시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 조직 진단 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 기술별, 질병 유형별, 최종 사용자별, 지역별 전망 및 예측(2023-2030년)
Global Tissue Diagnostics Market Size, Share & Trends Analysis Report By Product, By Technology, By Disease Type, By End User, By Regional Outlook and Forecast, 2023 - 2030
상품코드 : 1431198
리서치사 : KBV Research
발행일 : 2024년 01월
페이지 정보 : 영문 395 Pages
 라이선스 & 가격 (부가세 별도)
US $ 3,600 ￦ 5,006,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 4,320 ￦ 6,008,000
PDF (Multi User License) help
PDF 보고서를 동일 기업의 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,048 ￦ 8,411,000
PDF (Corporate User License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

조직 진단 시장 규모는 2030년까지 101억 달러에 달할 것으로 예상되며, 예측 기간 동안 연평균 9.1% 시장 성장률을 나타낼 것으로 예측됩니다.

또한 검사실과 진단센터에서는 코로나19 검사 수요가 급증하면서 우선순위가 바뀌었습니다. 인력과 장비 등 자원은 코로나19 검사 실시 및 처리에 투입됐습니다. 혼란을 완화하기 위해 원격 의료 및 디지털 병리 솔루션의 도입이 증가했습니다. 원격 진료, 가상 종양 보드, 디지털 슬라이드 공유가 널리 보급되어 병리학자들이 다양한 장소에서 조직 샘플을 분석할 수 있게 되었습니다. 따라서 COVID-19 전염병은 시장에 중간 정도의 영향을 미쳤습니다.

그러나 소규모 의료기관이나 검사실은 예산이 한정되어 있는 경우가 많아 고가의 조직 진단 장비를 구입하기 위해 많은 자금을 선투자하기 어렵습니다. 조직 검사 장비 및 세포 진단 장비 구매에 필요한 자본 지출은 이러한 조직의 재원을 압박할 수 있습니다. 자원이 한정된 환경에서 의료기관은 환자 치료, 기본 진단 장비, 인프라 등 필수적인 필요에 대한 지출에 우선순위를 두어야 할 수도 있습니다. 소규모 의료기관은 ROI(투자수익률)에 대한 명확한 이해 없이 고가의 장비에 투자하는 것을 꺼려할 수 있습니다. 진단 정확도 향상 및 환자 결과 개선과 같은 조직 진단의 임상적, 경제적 이점을 입증하는 것은 초기 비용과 지속적인 비용을 정당화하는 데 매우 중요합니다. 따라서 이러한 요인들은 향후 몇 년동안 조직진단 의약품에 대한 수요를 억제할 수 있습니다.

목차

제1장 시장 범위와 조사 방법

제2장 시장 요람

제3장 시장 개요

제4장 경쟁 분석 - 세계

제5장 세계의 조직진단 시장 : 제품별

제6장 세계의 조직진단 시장 : 기술별

제7장 세계의 조직진단 시장 : 질환 유형별

제8장 세계의 조직진단 시장 : 최종사용자별

제9장 세계의 조직진단 시장 : 지역별

제10장 기업 개요

제11장 조직진단 시장을 위한 성공 필수 조건

LSH
영문 목차

영문목차

The Global Tissue Diagnostics Market size is expected to reach $10.1 billion by 2030, rising at a market growth of 9.1% CAGR during the forecast period.

Prostate cancer is one of the most prevalent cancers in men, particularly in older age groups. Therefore, the Prostate cancer segment captured $544.4 million revenue in the market in 2022. The aging population, along with increased awareness and screening efforts, has led to the identification of more cases, driving the demand for prostate cancer diagnostics. Hence, these factors will lead to increased growth in the segment.

Tissue diagnostics, including techniques such as histopathology and cytology, are essential for the early detection and accurate diagnosis of cancer. Early diagnosis is critical for timely and effective treatment, improving patient outcomes. It helps identify specific biomarkers associated with different types of cancers. Biomarkers are molecular or cellular indicators that can signal the presence of cancer, its subtype, and its potential response to certain treatments. Tissue analysis allows for the identification and characterization of these biomarkers. Additionally, Immunohistochemistry involves the use of antibodies to detect specific proteins in tissue samples. When these antibodies bind to their target proteins, they produce a visible color change, allowing for identifying and localizing specific antigens within the tissue. In cancer diagnostics, IHC is frequently employed to identify particular biomarkers associated with distinct forms of cancer. It provides valuable information about the expression of proteins in cancer cells, aiding in the classification of tumors and guiding treatment decisions. Thus, these factors will help in the expansion of the market.

Further, laboratories and diagnostic centers experienced a surge in demand for COVID-19 testing, leading to a shift in priorities. Resources, including personnel and equipment, were redirected towards performing and processing COVID-19 tests. To mitigate disruptions, there was an increased adoption of telemedicine and digital pathology solutions. Remote consultations, virtual tumor boards, and digital slide sharing became more prevalent, allowing pathologists to analyze tissue samples from various locations. Therefore, the COVID-19 pandemic moderately impacted the market.

However, smaller healthcare facilities and laboratories often operate with constrained budgets, making it challenging to allocate significant funds to purchase expensive tissue diagnostics equipment upfront. The capital expenditure required for acquiring histology and cytology instruments can strain the financial resources of these organizations. In resource-limited settings, healthcare organizations may need to prioritize their spending on essential needs such as patient care, basic diagnostic equipment, and infrastructure. Smaller healthcare facilities may be cautious about investing in high-cost equipment without a clear understanding of the return on investment (ROI). Demonstrating the clinical and economic benefits of tissue diagnostics, including improved diagnostic accuracy and patient outcomes, becomes crucial in justifying the initial and ongoing costs. Thus, these factors can restrain the demand for tissue diagnostics in the coming years.

By Product Analysis

Based on product, the market is segmented into consumables and instruments. In 2022, the instruments segment garnered a significant revenue share in the market. Continuous technological progress has resulted in the creation of increasingly sophisticated and high-performing instruments utilized in tissue diagnostics. These instruments often incorporate innovative features such as automation, precision, and enhanced imaging capabilities, improving diagnostic processes' overall efficiency and accuracy. Thus, these factors will fuel the growth in the segment.

By Technology Analysis

On the basis of technology, the market is divided into immunohistochemistry, in situ hybridization, digital pathology & workflows, and special staining. The immunohistochemistry segment recorded the maximum revenue share in 2022. Immunohistochemistry plays a pivotal role in cancer diagnostics. It allows pathologists to identify and characterize specific proteins associated with different types of cancer. The growing prevalence of cancer cases worldwide has led to an increased demand for IHC for both diagnosis and prognosis. Thus, these aspects will lead to enhanced growth in the segment.

By Disease Type Analysis

Based on disease type, the market is divided into breast cancer, gastric cancer, lymphoma, prostate cancer, non-small cell lung cancer, and others. The gastric cancer segment procured a promising growth rate in 2022. Early detection is crucial for improving the outcomes of gastric cancer patients. Healthcare systems and organizations are increasingly emphasizing early detection and screening programs. It plays a pivotal role in confirming diagnoses and guiding treatment decisions at early stages. Therefore, the segment will grow rapidly in the upcoming years.

By End User Analysis

Based on end user, the market is segmented into hospitals, research laboratories, pharmaceutical organizations, contract research organizations (CROs), and others. The hospitals segment held the largest revenue share in 2022. Hospitals serve as comprehensive healthcare centers, providing a wide range of medical services, including diagnostics. Tissue diagnostics is an integral component of disease diagnosis, prognosis, and treatment planning, making it essential for hospitals to enhance their diagnostic capabilities. Therefore, these aspects will lead to enhanced growth in the segment.

By Regional Analysis

By region, the market is segmented into North America, Europe, Asia Pacific, and LAMEA. In 2022, the Europe segment acquired a considerable revenue share in the market. Europe has been witnessing a growing emphasis on personalized medicine, where tissue diagnostics play a crucial role. The development of genomics and molecular diagnostics has facilitated the customization of treatment approaches according to the unique characteristics of each patient. Hence, these aspects will propel the expansion of the segment.

The leading players in the market are competing with diverse innovative offerings to remain competitive in the market. The above illustration shows the percentage of revenue shared by some of the leading companies in the market. The leading players of the market are adopting various strategies in order to cater demand coming from the different industries. The key developmental strategies in the market are Acquisitions, and Partnerships & Collaborations.

Recent Strategies Deployed in the Market

List of Key Companies Profiled

Global Tissue Diagnostics Market Report Segmentation

By Product

By Technology

By Disease Type

By End User

By Geography

Table of Contents

Chapter 1. Market Scope & Methodology

Chapter 2. Market at a Glance

Chapter 3. Market Overview

Chapter 4. Competition Analysis - Global

Chapter 5. Global Tissue Diagnostics Market by Product

Chapter 6. Global Tissue Diagnostics Market by Technology

Chapter 7. Global Tissue Diagnostics Market by Disease Type

Chapter 8. Global Tissue Diagnostics Market by End User

Chapter 9. Global Tissue Diagnostics Market by Region

Chapter 10. Company Profiles

Chapter 11. Winning Imperatives for Tissue Diagnostics Market

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기